Drugs & TargetsFree BMS expands International Immuno-Oncology Network with addition of Columbia and MacCallum Cancer Centre March 03, 2017Vol.43 No.09
Drugs & TargetsFree Exelixis, BMS collaborate on late-stage combination trial in first-line RCC March 03, 2017Vol.43 No.09
Drugs & TargetsFree Exelixis, Roche to evaluate cabozantinib and atezolizumab in solid tumors March 03, 2017Vol.43 No.09
Drugs & TargetsFree Advaxis, SELLAS announce licensing agreement to develop antigen-targeting immunotherapy March 03, 2017Vol.43 No.09
Drugs & Targets FDA Approves Opdivo for Urothelial Carcinoma Indication February 28, 2017Vol.40 No.02
Drugs & Targets FDA approves marketing of 23andMe’s Bloom Syndrome carrier test February 27, 2017Vol.41 No.08
Drugs & TargetsFree FDA approves Revlimid as maintenance in multiple myeloma following transplant February 24, 2017Vol.43 No.08
Drugs & TargetsFree Zykadia receives a Priority Review for frontline use in ALK+ metastatic NSCLC February 24, 2017Vol.43 No.08
Drugs & TargetsFree FDA accepts Mylan’s BLA for biosimilar pegfilgrastim February 24, 2017Vol.43 No.08
Drugs & TargetsFree MIODx licenses immunotherapy technologies from UCSF February 24, 2017Vol.43 No.08
